NO3014045T3 - - Google Patents
Info
- Publication number
- NO3014045T3 NO3014045T3 NO14816715A NO14816715A NO3014045T3 NO 3014045 T3 NO3014045 T3 NO 3014045T3 NO 14816715 A NO14816715 A NO 14816715A NO 14816715 A NO14816715 A NO 14816715A NO 3014045 T3 NO3014045 T3 NO 3014045T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361789375P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO3014045T3 true NO3014045T3 (fr) | 2018-08-04 |
Family
ID=50639976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO14816715A NO3014045T3 (fr) | 2013-03-15 | 2014-06-26 |
Country Status (13)
Country | Link |
---|---|
US (3) | US10130649B2 (fr) |
EP (4) | EP3757570B1 (fr) |
CY (1) | CY1120507T1 (fr) |
DK (2) | DK2972360T3 (fr) |
ES (3) | ES2795249T3 (fr) |
HR (1) | HRP20180749T1 (fr) |
HU (1) | HUE039189T2 (fr) |
LT (1) | LT2972360T (fr) |
NO (1) | NO3014045T3 (fr) |
PT (1) | PT2972360T (fr) |
RS (1) | RS57316B1 (fr) |
SI (1) | SI2972360T1 (fr) |
WO (1) | WO2014144196A1 (fr) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ600616A (en) | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
DK2718269T3 (en) | 2011-06-08 | 2018-04-09 | Translate Bio Inc | SPLITLY LIPIDS |
KR102128248B1 (ko) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
DK2968586T3 (en) | 2013-03-14 | 2018-10-08 | Translate Bio Inc | CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
BR112016008832A2 (pt) * | 2013-10-22 | 2017-10-03 | Shire Human Genetic Therapies | Distribuição de mrna no snc e suas utilizações |
WO2015061500A1 (fr) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Thérapie arnm pour déficience en argininosuccinate synthétase |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの精製方法 |
JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
EP3364950A4 (fr) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
TW201729838A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
CN114404581A (zh) * | 2015-10-22 | 2022-04-29 | 摩登纳特斯有限公司 | 癌症疫苗 |
BR112018008090A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
JP6921833B2 (ja) * | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
EP3365008A4 (fr) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le virus respiratoire syncytial |
MA45209A (fr) * | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
EP3405579A1 (fr) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation |
US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
MA45041A (fr) * | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
CA3024507A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides codant pour l'?-galactosidase a pour le traitement de la maladie de fabry |
SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
US20190298657A1 (en) * | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
MY201498A (en) | 2016-05-18 | 2024-02-27 | Modernatx Inc | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
EP3315125A1 (fr) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Formulation de nanoparticules lipidiques |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3538136A1 (fr) * | 2016-11-10 | 2019-09-18 | Translate Bio, Inc. | Administration sous-cutanée d'arn messager |
IL266501B2 (en) * | 2016-11-10 | 2024-06-01 | Translate Bio Inc | An improved ICE-based lipid nanoparticle formulation for delivery of mRNA |
EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
WO2018165257A1 (fr) * | 2017-03-07 | 2018-09-13 | Translate Bio, Inc. | Administration polyanionique d'acides nucléiques |
EP3595713A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin contre le virus respiratoire syncytial |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
WO2019046809A1 (fr) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
EP3714048A1 (fr) | 2017-11-22 | 2020-09-30 | Modernatx, Inc. | Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée |
EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
CN112153985B (zh) * | 2018-04-25 | 2024-03-01 | 埃泽瑞斯公司 | 用于颗粒制剂的防冻剂 |
JP7448488B2 (ja) * | 2018-05-15 | 2024-03-12 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
AU2019288373A1 (en) * | 2018-06-19 | 2021-01-14 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
JP2021526845A (ja) | 2018-07-13 | 2021-10-11 | ゲンマブ エー/エス | Cd38抗体を使用したトロゴサイトーシスを介した治療 |
PE20211858A1 (es) | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2020051223A1 (fr) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions et procédés pour l'administration spécifique d'un organe d'acides nucléiques |
GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
MA53734A (fr) * | 2018-09-27 | 2021-08-04 | Modernatx Inc | Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase |
JP2022512578A (ja) | 2018-10-09 | 2022-02-07 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法 |
EP4031524A1 (fr) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Composés lipidiques de queue ramifiés et compositions pour l'administration intracellulaire d'agents thérapeutiques |
CN115461042A (zh) * | 2019-12-20 | 2022-12-09 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
CN115175698A (zh) | 2020-01-28 | 2022-10-11 | 摩登纳特斯有限公司 | 冠状病毒rna疫苗 |
WO2021159040A2 (fr) | 2020-02-07 | 2021-08-12 | Modernatx, Inc. | Vaccins à domaine arnm anti sars-cov-2 |
WO2021222304A1 (fr) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Vaccins à arn contre le sars-cov-2 |
WO2021159130A2 (fr) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Vaccins a arn de coronavirus et procédés d'utilisation |
US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
CA3094859A1 (fr) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Vesicules de proteolipide formulees avec petites proteines transmembranaires associees a la fusion |
US11771652B2 (en) * | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
WO2022150717A1 (fr) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Vaccins contre le virus de la grippe à arn saisonnière |
CA3208303A1 (fr) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Vaccins anti-coronavirus a base de souche variante |
JP2024503698A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | 変異型株ベースのコロナウイルスワクチン |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024511346A (ja) | 2021-03-15 | 2024-03-13 | モデルナティエックス インコーポレイテッド | Sars-cov-2 mrnaドメインワクチンの治療的使用 |
WO2022216787A2 (fr) * | 2021-04-08 | 2022-10-13 | City Of Hope | Nanoparticules lipidiques et leurs méthodes d'utilisation |
AU2022258335A1 (en) | 2021-04-13 | 2023-11-23 | Modernatx, Inc. | Respiratory virus combination vaccines |
WO2022221440A1 (fr) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Vaccins combinés contre le coronavirus et la grippe |
WO2022245888A1 (fr) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Vaccins à arn anti-grippe saisonnière et méthodes d'utilisation |
CA3224175A1 (fr) | 2021-06-18 | 2022-12-22 | Sanofi | Vaccins multivalents contre la grippe |
AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
AR127743A1 (es) | 2021-09-06 | 2024-02-28 | Genmab Bv | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos |
CA3231748A1 (fr) * | 2021-09-07 | 2023-03-16 | The Trustees Of The Univeristy Of Pennsylvania | Vaccin universel contre la grippe et methodes d'utilisation |
TW202330610A (zh) | 2021-10-08 | 2023-08-01 | 丹麥商珍美寶股份有限公司 | 結合至cd30及cd3之抗體 |
CA3235867A1 (fr) | 2021-10-22 | 2023-04-27 | Munir MOSAHEB | Composition de vaccin a base d'arnm |
WO2023073228A1 (fr) | 2021-10-29 | 2023-05-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
US20230302112A1 (en) | 2021-11-05 | 2023-09-28 | Sanofi | Respiratory synctial virus rna vaccine |
WO2023092069A1 (fr) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Vaccins à domaine arnm de sars-cov-2 et méthodes d'utilisation |
CA3238764A1 (fr) | 2021-11-23 | 2023-06-01 | Siddharth Patel | Composition lipidique derivee de bacteries et son utilisation |
WO2023102373A1 (fr) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Vaccins contre le métapneumovirus humain |
WO2023107999A2 (fr) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Vaccins à arnm contre le virus de l'herpès simplex |
WO2023111262A1 (fr) | 2021-12-17 | 2023-06-22 | Sanofi | Vaccin à base d'arn contre la maladie de lyme |
AU2022421841A1 (en) | 2021-12-20 | 2024-06-27 | Sail Biomedicines, Inc. | Mrna therapeutic compositions |
WO2023144330A1 (fr) | 2022-01-28 | 2023-08-03 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
WO2023196914A1 (fr) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Compositions d'acides nucléiques de la grippe et leurs utilisations |
TW202408567A (zh) | 2022-05-06 | 2024-03-01 | 法商賽諾菲公司 | 用於核酸疫苗之訊息序列 |
WO2023230481A1 (fr) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Vaccins contre l'orthopoxvirus |
WO2023227608A1 (fr) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli |
WO2024015890A1 (fr) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Vaccins à arnm de norovirus |
WO2024044108A1 (fr) | 2022-08-22 | 2024-02-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccins contre les coronavirus |
WO2024050483A1 (fr) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Vaccins contre le coronavirus à base de souche variante et utilisations associées |
WO2024083345A1 (fr) | 2022-10-21 | 2024-04-25 | BioNTech SE | Procédés et utilisations associés à des compositions liquides |
WO2024089638A1 (fr) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique |
WO2024094876A1 (fr) | 2022-11-04 | 2024-05-10 | Sanofi | Procédés d'extension d'arn messager |
WO2024094881A1 (fr) | 2022-11-04 | 2024-05-10 | Sanofi | Vaccination à arn contre le virus respiratoire syncytial |
WO2024102434A1 (fr) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Compositions d'arn comprenant des nanoparticules lipidiques ou des packs de messagers naturels reconstitués en packs lipidiques |
WO2024126847A1 (fr) | 2022-12-15 | 2024-06-20 | Sanofi | Enzymes de coiffage recombinantes d'arnm |
WO2024126809A1 (fr) | 2022-12-15 | 2024-06-20 | Sanofi | Arnm codant pour une particule de type virus de la grippe |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4946683A (en) | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
US5677124A (en) | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
FR2786104B1 (fr) * | 1998-11-25 | 2002-12-27 | Centre Nat Rech Scient | Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2004002453A1 (fr) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Appareil liposomal et procedes de fabrication |
WO2004060270A2 (fr) * | 2002-10-18 | 2004-07-22 | Genentech, Inc. | Compositions et methodes pour diagnostiquer et traiter des tumeurs |
AU2004272646B2 (en) | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
CA2569664C (fr) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Arn interferant encapsule dans des lipides |
EP1781593B1 (fr) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Lipides cationiques et leurs procédés d'utilisation |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
US20060216343A1 (en) * | 2004-11-05 | 2006-09-28 | Steffen Panzner | Pharmaceutical compositions comprising an oligonucleotide as an active agent |
WO2007031091A2 (fr) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Composes antagonistes d'arn de modulation de l'expression de p21 ras |
WO2007051303A1 (fr) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | Molecules d'arnsi modifiees et utilisations de celles-ci |
FR2904144A1 (fr) | 2006-07-19 | 2008-01-25 | St Microelectronics Rousset | Procede de fabrication d'un wafer de semi-conducteur comprenant un filtre optique integre |
EP2131848A4 (fr) | 2007-02-16 | 2012-06-27 | Merck Sharp & Dohme | Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives |
WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
WO2009046739A1 (fr) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition pour traiter le cancer de la prostate (pca) |
CA2910760C (fr) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Lipides de ciblage |
CA2710713C (fr) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencage de l'expression de la polo-like kinase a l'aide d'un arn interferent |
WO2009088891A1 (fr) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Procédé de criblage pour des compositions contenant des aminolipides sélectionnés |
JP5788312B2 (ja) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達 |
CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
WO2010037408A1 (fr) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition |
ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
KR20220150995A (ko) | 2008-11-10 | 2022-11-11 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
CA2750561C (fr) | 2009-01-26 | 2017-10-10 | Protiva Biotherapeutics, Inc. | Compositions et procedes d'inactivation de l'expression de l'apolipoproteine c-iii |
SG10201402054UA (en) | 2009-05-05 | 2014-09-26 | Muthiah Manoharan | Lipid compositions |
TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
WO2011000106A1 (fr) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques |
CA2767129C (fr) | 2009-07-01 | 2015-01-06 | Protiva Biotherapeutics, Inc. | Compositions et procedes permettant le silencage de l'apolipoproteine b |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
NZ600616A (en) | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP2509636B1 (fr) | 2009-12-07 | 2017-07-19 | Arbutus Biopharma Corporation | Compositions utilisées pour l'administration d'acides nucléiques |
WO2011069529A1 (fr) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques |
CA2784568A1 (fr) | 2009-12-18 | 2011-06-23 | Martin A. Maier | Particules de lipide destinees a la distribution d'acides nucleiques |
JP2013527856A (ja) | 2010-05-12 | 2013-07-04 | プロチバ バイオセラピューティクス インコーポレイティッド | 陽イオン性脂質およびその使用方法 |
WO2012000104A1 (fr) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Systèmes non liposomaux pour une administration d'acide nucléique |
WO2012016184A2 (fr) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour la délivrance d'agents actifs |
CA2807552A1 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucleiques modifies et leurs procedes d'utilisation |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
WO2012075040A2 (fr) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | Arnm pour l'utilisation dans le traitement de maladies génétiques humaines |
WO2012116715A1 (fr) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des nouveaux-nés et des enfants en bas âge |
WO2012113413A1 (fr) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Composition de vaccin comprenant des acides nucléiques immunostimulateurs complexés et des antigènes emballés avec des conjugués de polyéthylèneglycol/peptide à liaison disulfure |
WO2012116714A1 (fr) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des patients âgés |
WO2012135805A2 (fr) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Administration et formulation d'acides nucléiques génétiquement modifiés |
WO2012158736A1 (fr) | 2011-05-17 | 2012-11-22 | modeRNA Therapeutics | Acides nucléiques manipulés et leurs procédés d'utilisation pour des vertébrés non humains |
DK2718269T3 (en) | 2011-06-08 | 2018-04-09 | Translate Bio Inc | SPLITLY LIPIDS |
KR102128248B1 (ko) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
EP2755986A4 (fr) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | Acides nucléiques modifiés et leurs procédés d'utilisation |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013039861A2 (fr) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Acides nucléiques modifiés et leurs procédés d'utilisation |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
EP3424564A1 (fr) * | 2011-10-31 | 2019-01-09 | Mallinckrodt LLC | Compositions liposomales combinatoires pour le traitement du cancer |
EP2791364A4 (fr) | 2011-12-14 | 2015-11-11 | Moderna Therapeutics Inc | Procédés de réponse à une menace biologique |
US20140343129A1 (en) | 2011-12-14 | 2014-11-20 | Moderna Therapeutics, Inc. | Modified nucleic acids, and acute care uses thereof |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
WO2013096709A2 (fr) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Procédés d'augmentation de la viabilité ou de la longévité d'un organe ou d'un explant d'organe |
US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
WO2013120497A1 (fr) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Acide nucléique comprenant ou codant pour une tige-boucle d'histone et une séquence poly(a) ou un signal de polyadénylation pour l'augmentation de l'expression d'une protéine thérapeutique codée |
WO2013120499A1 (fr) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Acide nucléique comprenant ou codant pour une tige-boucle d'histone et une séquence poly(a) ou un signal de polyadénylation pour augmenter l'expression d'un antigène pathogène codé |
KR102384791B1 (ko) | 2012-02-24 | 2022-04-08 | 아뷰터스 바이오파마 코포레이션 | 트리알킬 양이온성 지질 및 그의 사용 방법 |
RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151666A2 (fr) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine |
US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
EP2833892A4 (fr) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Polynucléotides modifiés destinés à la production de protéines et de peptides associés à l'oncologie |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US9636301B2 (en) | 2012-12-04 | 2017-05-02 | Arbutus Biopharma Corporation | In vitro release assay for liposome encapsulated vincristine |
WO2014089486A1 (fr) | 2012-12-07 | 2014-06-12 | Shire Human Genetic Therapies, Inc. | Nanoparticules lipidiques pour administration de marn |
WO2014093574A1 (fr) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Polynucléotides modifiés pour modifier le phénotype cellulaire |
JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
WO2014158795A1 (fr) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnostic et traitement de la fibrose |
WO2014159813A1 (fr) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Molécules polynucléotidiques à longue durée de vie |
WO2014152211A1 (fr) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés |
WO2014152030A1 (fr) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Elimination de fragments d'adn dans des procédés de production d'arnm |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014152027A1 (fr) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Procédés de fabrication pour la production de transcrits d'arn |
WO2014144767A1 (fr) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Purification d'arnm par échange d'ions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP3971287A1 (fr) | 2013-07-11 | 2022-03-23 | ModernaTX, Inc. | Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation |
CN110974981A (zh) | 2013-07-23 | 2020-04-10 | 野草莓树生物制药公司 | 用于递送信使rna的组合物和方法 |
BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
US20160264614A1 (en) | 2013-10-02 | 2016-09-15 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015051169A2 (fr) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Molécules de polynucléotides et leurs utilisations |
EP3058082A4 (fr) | 2013-10-18 | 2017-04-26 | ModernaTX, Inc. | Compositions et procédés pour tolériser des systèmes cellulaires |
CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
US20170173128A1 (en) | 2013-12-06 | 2017-06-22 | Moderna TX, Inc. | Targeted adaptive vaccines |
EP3053585A1 (fr) | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique alternatives et utilisations associées |
JP6704850B2 (ja) | 2013-12-30 | 2020-06-03 | キュアバック アーゲー | 人工核酸分子 |
US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
WO2015135558A1 (fr) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combinaison de vaccination et d'agonistes de ox40 |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
ES2727776T3 (es) | 2014-06-10 | 2019-10-18 | Curevac Ag | Método para mejorar la producción de ARN |
US20170175129A1 (en) | 2014-06-19 | 2017-06-22 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
EP3157573A4 (fr) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique alternatives et leurs utilisations |
WO2015196118A1 (fr) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique différentes et utilisations |
ES2834556T3 (es) | 2014-06-25 | 2021-06-17 | Acuitas Therapeutics Inc | Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos |
WO2016005004A1 (fr) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilisation de séquences d'adn codant pour une séquence poly (a) |
CA2963271A1 (fr) | 2014-10-02 | 2016-04-07 | Protiva Biotherapeutics, Inc. | Compositions et methodes d'extinction de l'expression du gene du virus de l'hepatite b |
WO2016071857A1 (fr) | 2014-11-07 | 2016-05-12 | Protiva Biotherapeutics, Inc. | Compositions et méthodes pour le silençage de l'expression du virus ebola |
WO2016077125A1 (fr) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique de remplacement contenant une quantité réduite d'uracile et utilisations associées |
US20170362627A1 (en) | 2014-11-10 | 2017-12-21 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
EP3247363A4 (fr) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
US20180085474A1 (en) | 2015-01-23 | 2018-03-29 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016154127A2 (fr) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions et méthodes pour traiter l'hypertriglycéridémie |
WO2016164762A1 (fr) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucléotides codant pour des mutants, au niveau des domaines egf-a et intracellulaire, du récepteur des lipoprotéines basse densité et et leurs procédés d'utilisation |
WO2016183366A2 (fr) | 2015-05-12 | 2016-11-17 | Protiva Biotherapeutics, Inc. | Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d |
US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
WO2016197133A1 (fr) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics, Inc. | Administration d'agents thérapeutiques crispr avec des nanoparticules de lipide |
EP3307305A4 (fr) | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | Vaccins adaptatifs ciblés |
WO2017019891A2 (fr) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b |
JP2018527003A (ja) | 2015-09-17 | 2018-09-20 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 安定化尾部領域を含むポリヌクレオチド |
WO2017049286A1 (fr) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucléotides contenant un lieur morpholino |
US20190054112A1 (en) | 2015-09-18 | 2019-02-21 | Moderna Therapeutics, Inc. | Polynucleotide formulations for use in the treatment of renal diseases |
WO2017102010A1 (fr) | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Nouvelles protéines de fusion à cytokine |
WO2017108087A1 (fr) | 2015-12-21 | 2017-06-29 | Curevac Ag | Incrustation pour plaque de culture et procédé de préparation de système de plaque de culture correspondant doté d'une telle incrustation |
WO2017109134A1 (fr) | 2015-12-22 | 2017-06-29 | Curevac Ag | Procédé de production de compositions de molécules d'arn |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
USD787703S1 (en) | 2016-04-26 | 2017-05-23 | Curevac Ag | Inlay for a culture plate |
-
2014
- 2014-03-14 EP EP20169318.1A patent/EP3757570B1/fr active Active
- 2014-03-14 WO PCT/US2014/028498 patent/WO2014144196A1/fr active Application Filing
- 2014-03-14 HU HUE14721647A patent/HUE039189T2/hu unknown
- 2014-03-14 RS RS20180551A patent/RS57316B1/sr unknown
- 2014-03-14 ES ES18160237T patent/ES2795249T3/es active Active
- 2014-03-14 US US14/775,818 patent/US10130649B2/en active Active
- 2014-03-14 DK DK14721647.7T patent/DK2972360T3/en active
- 2014-03-14 ES ES14721647.7T patent/ES2670529T3/es active Active
- 2014-03-14 PT PT147216477T patent/PT2972360T/pt unknown
- 2014-03-14 EP EP18160237.6A patent/EP3388834B1/fr active Active
- 2014-03-14 SI SI201430708T patent/SI2972360T1/en unknown
- 2014-03-14 ES ES20169318T patent/ES2967701T3/es active Active
- 2014-03-14 EP EP14721647.7A patent/EP2972360B1/fr active Active
- 2014-03-14 LT LTEP14721647.7T patent/LT2972360T/lt unknown
- 2014-03-14 DK DK18160237.6T patent/DK3388834T3/da active
- 2014-03-14 EP EP23202696.3A patent/EP4332576A3/fr active Pending
- 2014-06-26 NO NO14816715A patent/NO3014045T3/no unknown
-
2018
- 2018-05-14 HR HRP20180749TT patent/HRP20180749T1/hr unknown
- 2018-05-23 CY CY20181100543T patent/CY1120507T1/el unknown
- 2018-10-10 US US16/157,050 patent/US10646504B2/en active Active
-
2020
- 2020-03-31 US US16/836,513 patent/US20200390797A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CY1120507T1 (el) | 2019-07-10 |
HRP20180749T1 (hr) | 2018-08-10 |
US10130649B2 (en) | 2018-11-20 |
EP4332576A2 (fr) | 2024-03-06 |
DK2972360T3 (en) | 2018-05-22 |
SI2972360T1 (en) | 2018-08-31 |
US10646504B2 (en) | 2020-05-12 |
EP3757570C0 (fr) | 2023-10-11 |
EP3757570A1 (fr) | 2020-12-30 |
US20200390797A1 (en) | 2020-12-17 |
EP2972360A1 (fr) | 2016-01-20 |
EP3757570B1 (fr) | 2023-10-11 |
EP3388834A1 (fr) | 2018-10-17 |
HUE039189T2 (hu) | 2018-12-28 |
EP2972360B1 (fr) | 2018-03-07 |
ES2795249T3 (es) | 2020-11-23 |
RS57316B1 (sr) | 2018-08-31 |
ES2967701T3 (es) | 2024-05-03 |
PT2972360T (pt) | 2018-05-25 |
LT2972360T (lt) | 2018-09-10 |
US20190216843A1 (en) | 2019-07-18 |
ES2670529T3 (es) | 2018-05-30 |
EP3388834B1 (fr) | 2020-04-15 |
WO2014144196A1 (fr) | 2014-09-18 |
US20160151409A1 (en) | 2016-06-02 |
DK3388834T3 (da) | 2020-05-04 |
EP4332576A3 (fr) | 2024-04-24 |